Program Type: ICER

COVID-19, 2020

Policy Paper

An assessment of COVID-19 treatments, including remdesivir and dexamethasone  On May 1st, ICER released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) […]